Avoro Capital Advisors LLC 13D and 13G filings for Monte Rosa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 09:30 am Sale | 2024-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Avoro Capital Advisors LLC | 4,345,000 7.100% | -190,000 (-4.19%) | Filing |
| 2024-02-14 09:14 am Purchase | 2023-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Avoro Capital Advisors LLC | 4,535,000 9.100% | 210,000 (+4.86%) | Filing |
| 2023-02-14 09:40 am Purchase | 2022-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Avoro Capital Advisors LLC | 4,325,000 8.900% | 1,013,566 (+30.61%) | Filing |
| 2022-02-11 10:06 am Purchase | 2021-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Avoro Capital Advisors LLC | 3,311,434 7.100% | 3,311,434 (New Position) | Filing |